Aclaris Therapeutics(ACRS) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis- -Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immunoinflammatory diseases, today annou ...